BLAINTRAVENOUSVIALPriority Review
Approved
May 2001
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
5/8 — Partial
Priority Review
CAMPATH (alemtuzumab) by Sanofi is cd52-directed antibody interactions [moa]. Approved for chronic lymphocytic leukemia, multiple sclerosis, kidney transplantation. First approved in 2001.
Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CAMPATH (alemtuzumab) is a CD52-directed monoclonal antibody that depletes lymphocytes through cytolytic mechanisms. It is approved for chronic lymphocytic leukemia, multiple sclerosis, and kidney transplantation. The drug targets CD52 antigen on B and T lymphocytes, making it effective in conditions driven by aberrant lymphocyte populations.
LOE Approaching
As an older biologic approaching loss of exclusivity with moderate competitive pressure (30/100), teams are likely focused on lifecycle extension and managed decline rather than growth initiatives.
Mechanism of Action
CD52-directed Antibody Interactions
Pharmacologic Class:
CD52-directed Cytolytic Antibody
Indications (3)
Worked on CAMPATH at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.